{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:40:28Z","timestamp":1783633228795,"version":"3.55.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s11060-024-04670-x","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T02:01:29Z","timestamp":1715997689000},"page":"197-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Medical treatment of functional pituitary adenomas, trials and tribulations"],"prefix":"10.1007","volume":"168","author":[{"given":"Cristina","family":"Capatina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia Alexandra","family":"Hanzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Hinojosa-Amaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"key":"4670_CR1","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","volume":"43","author":"S Melmed","year":"2022","unstructured":"Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY (2022) Clinical Biology of the Pituitary Adenoma. Endocr Rev 43:1003\u20131037. https:\/\/doi.org\/10.1210\/endrev\/bnac010","journal-title":"Endocr Rev"},{"key":"4670_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","volume":"49","author":"AF Daly","year":"2020","unstructured":"Daly AF, Beckers A (2020) The Epidemiology of Pituitary Adenomas. Endocrinol Metab Clin North Am 49:347\u2013355. https:\/\/doi.org\/10.1016\/j.ecl.2020.04.002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"4670_CR3","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1001\/jama.2023.5444","volume":"329","author":"NA Tritos","year":"2023","unstructured":"Tritos NA, Miller KK (2023) Diagnosis and Management of Pituitary Adenomas: A Review. JAMA 329:1386\u20131398. https:\/\/doi.org\/10.1001\/jama.2023.5444","journal-title":"JAMA"},{"key":"4670_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1530\/EJE-15-0189","volume":"173","author":"TT Agustsson","year":"2015","unstructured":"Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R (2015) The epidemiology of pituitary adenomas in Iceland, 1955\u20132012: a nationwide population-based study. Eur J Endocrinol 173:655\u2013664. https:\/\/doi.org\/10.1530\/EJE-15-0189","journal-title":"Eur J Endocrinol"},{"key":"4670_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000497746","volume":"109","author":"L Vroonen","year":"2019","unstructured":"Vroonen L, Daly AF, Beckers A (2019) Epidemiology and Management Challenges in Prolactinomas. Neuroendocrinology 109:20\u201327. https:\/\/doi.org\/10.1159\/000497746","journal-title":"Neuroendocrinology"},{"key":"4670_CR6","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab 33:101290. https:\/\/doi.org\/10.1016\/j.beem.2019.101290","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"4670_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00886-5","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson SL, Shimon I, Spencer-Segal J, Vila G, Wass J, Melmed S (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"key":"4670_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000495184","volume":"109","author":"I Shimon","year":"2019","unstructured":"Shimon I (2019) Giant Prolactinomas. Neuroendocrinology 109:51\u201356. https:\/\/doi.org\/10.1159\/000495184","journal-title":"Neuroendocrinology"},{"key":"4670_CR9","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","volume":"108","author":"RS Auriemma","year":"2023","unstructured":"Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R (2023) Approach to the Patient With Prolactinoma. J Clin Endocrinol Metab 108:2400\u20132423. https:\/\/doi.org\/10.1210\/clinem\/dgad174","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR10","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1210\/jcem.85.6.6657","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247\u20132252. https:\/\/doi.org\/10.1210\/jcem.85.6.6657","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.20945\/2359-3997000000032","volume":"62","author":"L Vilar","year":"2018","unstructured":"Vilar L, Abucham J, Albuquerque JL, Araujo LA, Azevedo MF, Boguszewski CL, Casulari LA, Cunha Neto MBC, Czepielewski MA, Duarte FHG, Faria MDS, Gadelha MR, Garmes HM, Glezer A, Gurgel MH, Jallad RS, Martins M, Miranda PAC, Montenegro RM, Musolino NRC, Naves LA, Ribeiro-Oliveira Junior A, Silva CMS, Viecceli C, Bronstein MD (2018) Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab 62:236\u2013263. https:\/\/doi.org\/10.20945\/2359-3997000000032","journal-title":"Arch Endocrinol Metab"},{"key":"4670_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/EJE-21-0561","volume":"185","author":"B Biagetti","year":"2021","unstructured":"Biagetti B, Sarria-Estrada S, Ng-Wong YK, Martinez-Saez E, Casteras A, Cordero Asanza E, Hernandez I, Giralt-Arnaiz M, Simo R (2021) Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. Eur J Endocrinol 185:587\u2013595. https:\/\/doi.org\/10.1530\/EJE-21-0561","journal-title":"Eur J Endocrinol"},{"key":"4670_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3803\/EnM.2014.29.3.280","volume":"29","author":"Y Lee","year":"2014","unstructured":"Lee Y, Ku CR, Kim EH, Hong JW, Lee EJ, Kim SH (2014) Early prediction of long-term response to cabergoline in patients with macroprolactinomas. Endocrinol Metab (Seoul) 29:280\u2013292. https:\/\/doi.org\/10.3803\/EnM.2014.29.3.280","journal-title":"Endocrinol Metab (Seoul)"},{"key":"4670_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11102-020-01039-x","volume":"23","author":"V Bonert","year":"2020","unstructured":"Bonert V (2020) Do nothing but observe microprolactinomas: when and how to replace sex hormones? Pituitary 23:307\u2013313. https:\/\/doi.org\/10.1007\/s11102-020-01039-x","journal-title":"Pituitary"},{"key":"4670_CR15","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s12020-019-01962-5","volume":"65","author":"I Shimon","year":"2019","unstructured":"Shimon I, Hirsch D, Tsvetov G, Robenshtok E, Akirov A, Fraenkel M, Eizenberg Y, Herzberg D, Barzilay-Yoseph L, Livner A, Friedrich I, Manisterski Y, Ishay A, Yoel U, Masri H (2019) Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years. Endocrine 65:656\u2013661. https:\/\/doi.org\/10.1007\/s12020-019-01962-5","journal-title":"Endocrine"},{"key":"4670_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12902-021-00733-6","volume":"21","author":"AS Posawetz","year":"2021","unstructured":"Posawetz AS, Trummer C, Pandis M, Aberer F, Pieber TR, Obermayer-Pietsch B, Pilz S, Theiler-Schwetz V (2021) Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study. BMC Endocr Disord 21:81. https:\/\/doi.org\/10.1186\/s12902-021-00733-6","journal-title":"BMC Endocr Disord"},{"key":"4670_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000371851","volume":"101","author":"RS Auriemma","year":"2015","unstructured":"Auriemma RS, Galdiero M, Vitale P, Granieri L, Lo Calzo F, Salzano C, Ferreri L, Pivonello C, Cariati F, Coppola G, de Angelis C, Colao A, Pivonello R (2015) Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology 101:66\u201381. https:\/\/doi.org\/10.1159\/000371851","journal-title":"Neuroendocrinology"},{"key":"4670_CR18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11154-022-09753-6","volume":"23","author":"A Hamidianjahromi","year":"2022","unstructured":"Hamidianjahromi A, Tritos NA (2022) Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Rev Endocr Metab Disord 23:1089\u20131099. https:\/\/doi.org\/10.1007\/s11154-022-09753-6","journal-title":"Rev Endocr Metab Disord"},{"key":"4670_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000497331","volume":"109","author":"M Buchfelder","year":"2019","unstructured":"Buchfelder M, Zhao Y, Schlaffer SM (2019) Surgery for Prolactinomas to Date. Neuroendocrinology 109:77\u201381. https:\/\/doi.org\/10.1159\/000497331","journal-title":"Neuroendocrinology"},{"key":"4670_CR20","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-21-0462","volume":"185","author":"A Luger","year":"2021","unstructured":"Luger A, Broersen LHA, Biermasz NR, Biller BMK, Buchfelder M, Chanson P, Jorgensen JOL, Kelestimur F, Llahana S, Maiter D, Mintziori G, Petraglia F, Verkauskiene R, Webb SM, Dekkers OM (2021) ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol 185:G1\u2013G33. https:\/\/doi.org\/10.1530\/EJE-21-0462","journal-title":"Eur J Endocrinol"},{"key":"4670_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000094312","volume":"35","author":"M Guitelman","year":"2006","unstructured":"Guitelman M (2006) Long-term follow-up of prolactinomas: should dopamine agonist treatment be life-long? Front Horm Res 35:88\u2013101. https:\/\/doi.org\/10.1159\/000094312","journal-title":"Front Horm Res"},{"key":"4670_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","volume":"20","author":"Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, Melmed S, Mortini P, Wass J, Giustina A, Pituitary Society EGoPT","year":"2017","unstructured":"Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, Melmed S, Mortini P, Wass J, Giustina A, Pituitary Society EGoPT (2017) Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary 20:489\u2013498. https:\/\/doi.org\/10.1007\/s11102-017-0838-2","journal-title":"Pituitary"},{"key":"4670_CR23","doi-asserted-by":"publisher","unstructured":"Fukuhara N, Nishiyama M, Iwasaki Y (2022) Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14153604","DOI":"10.3390\/cancers14153604"},{"key":"4670_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter D (2019) Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology 109:42\u201350. https:\/\/doi.org\/10.1159\/000495775","journal-title":"Neuroendocrinology"},{"key":"4670_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/a-1247-4908","volume":"129","author":"S Giese","year":"2021","unstructured":"Giese S, Nasi-Kordhishti I, Honegger J (2021) Outcomes of Transsphenoidal Microsurgery for Prolactinomas - A Contemporary Series of 162 Cases. Exp Clin Endocrinol Diabetes 129:163\u2013171. https:\/\/doi.org\/10.1055\/a-1247-4908","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"4670_CR26","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-16-0087","volume":"175","author":"M Tampourlou","year":"2016","unstructured":"Tampourlou M, Trifanescu R, Paluzzi A, Ahmed SK, Karavitaki N (2016) Therapy of endocrine disease: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur J Endocrinol 175:R89-96. https:\/\/doi.org\/10.1530\/EJE-16-0087","journal-title":"Eur J Endocrinol"},{"key":"4670_CR27","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.clineuro.2013.02.016","volume":"115","author":"H Ikeda","year":"2013","unstructured":"Ikeda H, Watanabe K, Tominaga T, Yoshimoto T (2013) Transsphenoidal microsurgical results of female patients with prolactinomas. Clin Neurol Neurosurg 115:1621\u20131625. https:\/\/doi.org\/10.1016\/j.clineuro.2013.02.016","journal-title":"Clin Neurol Neurosurg"},{"key":"4670_CR28","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","volume":"105","author":"AH Zamanipoor Najafabadi","year":"2020","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM, Peul WC, Dekkers OM, van Furth WR, Biermasz NR (2020) Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 105:e32-41. https:\/\/doi.org\/10.1210\/clinem\/dgz144","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR29","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10:804\u2013826. https:\/\/doi.org\/10.1016\/S2213-8587(22)00244-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4670_CR30","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00701-016-2903-4","volume":"158","author":"D Starnoni","year":"2016","unstructured":"Starnoni D, Daniel RT, Marino L, Pitteloud N, Levivier M, Messerer M (2016) Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. Acta Neurochir (Wien) 158:2109\u20132121. https:\/\/doi.org\/10.1007\/s00701-016-2903-4","journal-title":"Acta Neurochir (Wien)"},{"key":"4670_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.17925\/EE.2019.15.1.30","volume":"15","author":"EV Varlamov","year":"2019","unstructured":"Varlamov EV, McCartney S, Fleseriu M (2019) Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies. Eur Endocrinol 15:30\u201340. https:\/\/doi.org\/10.17925\/EE.2019.15.1.30","journal-title":"Eur Endocrinol"},{"key":"4670_CR32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1530\/eje.1.01863","volume":"152","author":"P Nomikos","year":"2005","unstructured":"Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical \u201ccure.\u201d Eur J Endocrinol 152:379\u2013387. https:\/\/doi.org\/10.1530\/eje.1.01863","journal-title":"Eur J Endocrinol"},{"key":"4670_CR33","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s11102-017-0813-y","volume":"20","author":"C Fernandez Mateos","year":"2017","unstructured":"Fernandez Mateos C, Garcia-Uria M, Morante TL, Garcia-Uria J (2017) Acromegaly: surgical results in 548 patients. Pituitary 20:522\u2013528. https:\/\/doi.org\/10.1007\/s11102-017-0813-y","journal-title":"Pituitary"},{"key":"4670_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24:1\u201313. https:\/\/doi.org\/10.1007\/s11102-020-01091-7","journal-title":"Pituitary"},{"key":"4670_CR35","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S (2020) Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord 21:667\u2013678. https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev Endocr Metab Disord"},{"key":"4670_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrendo.2014.21","volume":"10","author":"A Giustina","year":"2014","unstructured":"Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S, Acromegaly Consensus G (2014) Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10:243\u2013248. https:\/\/doi.org\/10.1038\/nrendo.2014.21","journal-title":"Nat Rev Endocrinol"},{"key":"4670_CR37","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A (2018) A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14:552\u2013561. https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"key":"4670_CR38","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/jc.2013-3757","volume":"99","author":"JD Carmichael","year":"2014","unstructured":"Carmichael JD, Bonert VS, Nuno M, Ly D, Melmed S (2014) Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab 99:1825\u20131833. https:\/\/doi.org\/10.1210\/jc.2013-3757","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR39","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1210\/jc.2004-2466","volume":"90","author":"S Melmed","year":"2005","unstructured":"Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405\u20134410. https:\/\/doi.org\/10.1210\/jc.2004-2466","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2265.2008.03503.x","volume":"71","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E, Minuto F, Lombardi G, Pivonello R, Ferone D (2009) Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 71:237\u2013245. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03503.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"4670_CR41","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prevost G, Maisonobe P, Clermont A, Investigators P (2014) Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 99:1282\u20131290. https:\/\/doi.org\/10.1210\/jc.2013-3318","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11102-015-0693-y","volume":"19","author":"Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, Webb SM, Group PI","year":"2016","unstructured":"Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, Webb SM, Group PI (2016) Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary 19:149\u2013157. https:\/\/doi.org\/10.1007\/s11102-015-0693-y","journal-title":"Pituitary"},{"key":"4670_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/EJE-09-0372","volume":"161","author":"A Giustina","year":"2009","unstructured":"Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, de Marinis L, Degli Uberti E, Bogazzi F, Mazziotti G, Minuto F, Montini M, Ghigo E (2009) High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 161:331\u2013338. https:\/\/doi.org\/10.1530\/EJE-09-0372","journal-title":"Eur J Endocrinol"},{"key":"4670_CR44","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1210\/jc.2017-00142","volume":"102","author":"A Giustina","year":"2017","unstructured":"Giustina A, Mazziotti G, Cannavo S, Castello R, Arnaldi G, Bugari G, Cozzi R, Ferone D, Formenti AM, Gatti E, Grottoli S, Maffei P, Maffezzoni F, Montini M, Terzolo M, Ghigo E (2017) High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. J Clin Endocrinol Metab 102:2454\u20132464. https:\/\/doi.org\/10.1210\/jc.2017-00142","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11102-022-01285-1","volume":"26","author":"M Fleseriu","year":"2023","unstructured":"Fleseriu M, Zhang Z, Hanman K, Haria K, Houchard A, Khawaja S, Ribeiro-Oliveira A Jr, Gadelha M (2023) A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly. Pituitary 26:9\u201341. https:\/\/doi.org\/10.1007\/s11102-022-01285-1","journal-title":"Pituitary"},{"key":"4670_CR46","doi-asserted-by":"publisher","first-page":"e3644","DOI":"10.1210\/clinem\/dgac385","volume":"107","author":"L Maione","year":"2022","unstructured":"Maione L, Albrici C, Grunenwald S, Mouly C, Cimino V, Lecoq AL, Souberbielle JC, Caron P, Chanson P (2022) IGF-I Variability Over Repeated Measures in Patients With Acromegaly Under Long-Acting Somatostatin Receptor Ligands. J Clin Endocrinol Metab 107:e3644\u2013e3653. https:\/\/doi.org\/10.1210\/clinem\/dgac385","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR47","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1530\/EJE-15-1042","volume":"174","author":"CJ Strasburger","year":"2016","unstructured":"Strasburger CJ, Karavitaki N, Stormann S, Trainer PJ, Kreitschmann-Andermahr I, Droste M, Korbonits M, Feldmann B, Zopf K, Sanderson VF, Schwicker D, Gelbaum D, Haviv A, Bidlingmaier M, Biermasz NR (2016) Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol 174:355\u2013362. https:\/\/doi.org\/10.1530\/EJE-15-1042","journal-title":"Eur J Endocrinol"},{"key":"4670_CR48","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","volume":"23","author":"EB Geer","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Gelbaum D, Liu S, Mathias SD, Shi L (2020) Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary 23:140\u2013148. https:\/\/doi.org\/10.1007\/s11102-019-01013-2","journal-title":"Pituitary"},{"key":"4670_CR49","doi-asserted-by":"publisher","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","volume":"105","author":"SL Samson","year":"2020","unstructured":"Samson SL, Nachtigall LB, Fleseriu M, Gordon MB, Bolanowski M, Labadzhyan A, Ur E, Molitch M, Ludlam WH, Patou G, Haviv A, Biermasz N, Giustina A, Trainer PJ, Strasburger CJ, Kennedy L, Melmed S (2020) Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. J Clin Endocrinol Metab 105:e3785-3797. https:\/\/doi.org\/10.1210\/clinem\/dgaa526","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR50","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1210\/clinem\/dgac643","volume":"108","author":"MR Gadelha","year":"2023","unstructured":"Gadelha MR, Gordon MB, Doknic M, Mezosi E, Toth M, Randeva H, Marmon T, Jochelson T, Luo R, Monahan M, Madan A, Ferrara-Cook C, Struthers RS, Krasner A (2023) ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly. J Clin Endocrinol Metab 108:e148\u2013e159. https:\/\/doi.org\/10.1210\/clinem\/dgac643","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR51","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1210\/jc.2012-1179","volume":"97","author":"S Tuvia","year":"2012","unstructured":"Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D, Landau I, Karmeli I, Bidlingmaier M, Strasburger CJ, Kleinberg DL, Melmed S, Mamluk R (2012) Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 97:2362\u20132369. https:\/\/doi.org\/10.1210\/jc.2012-1179","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR52","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s11102-021-01163-2","volume":"24","author":"A Labadzhyan","year":"2021","unstructured":"Labadzhyan A, Nachtigall LB, Fleseriu M, Gordon MB, Molitch M, Kennedy L, Samson SL, Greenman Y, Biermasz N, Bolanowski M, Haviv A, Ludlam W, Patou G, Strasburger CJ (2021) Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. Pituitary 24:943\u2013953. https:\/\/doi.org\/10.1007\/s11102-021-01163-2","journal-title":"Pituitary"},{"key":"4670_CR53","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, Melmed S, Strasburger CJ (2022) Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 10:102\u2013111. https:\/\/doi.org\/10.1016\/S2213-8587(21)00296-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4670_CR54","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad365","author":"M Fleseriu","year":"2023","unstructured":"Fleseriu M, Molitch M, Dreval A, Pokramovich Y, Bondar I, Poteshkin Y, Macut D, Obermayer-Pietsch B, Gilgun-Sherki Y, Haviv A, Biermasz N, Strasburger CJ (2023) MPOWERED Trial Open-Label Extension: Long-Term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgad365","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR55","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Resendiz K, Ruffin M, Chen Y, Sheppard M, Pasireotide CSG (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791\u2013799. https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR56","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1210\/jc.2009-2272","volume":"95","author":"Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM, Pasireotide Acromegaly Study G","year":"2010","unstructured":"Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM, Pasireotide Acromegaly Study G (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95:2781\u20132789. https:\/\/doi.org\/10.1210\/jc.2009-2272","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR57","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","volume":"182","author":"A Colao","year":"2020","unstructured":"Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, Raverot G, Shimon I, Fleck J, Gupta P, Pedroncelli AM, Gadelha MR (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol 182:583. https:\/\/doi.org\/10.1530\/EJE-19-0762","journal-title":"Eur J Endocrinol"},{"key":"4670_CR58","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A, Pasireotide CSG (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2:875\u2013884. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4670_CR59","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I, van der Lely AJ, Ravichandran S, Kandra A, Pedroncelli AM, Colao AAL (2020) Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect 9:1178\u20131190. https:\/\/doi.org\/10.1530\/EC-20-0361","journal-title":"Endocr Connect"},{"key":"4670_CR60","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1210\/jcem-38-2-200","volume":"38","author":"PG Chiodini","year":"1974","unstructured":"Chiodini PG, Liuzzi A, Botalla L, Cremascoli G, Silvestrini F (1974) Inhibitory effect of dopaminergic stimulation on GH release in acromegaly. J Clin Endocrinol Metab 38:200\u2013206. https:\/\/doi.org\/10.1210\/jcem-38-2-200","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR61","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1210\/jcem-55-4-734","volume":"55","author":"A Spada","year":"1982","unstructured":"Spada A, Sartorio A, Bassetti M, Pezzo G, Giannattasio G (1982) In vitro effect of dopamine on growth hormone (GH) release from human GH-secreting pituitary adenomas. J Clin Endocrinol Metab 55:734\u2013740. https:\/\/doi.org\/10.1210\/jcem-55-4-734","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR62","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1210\/jc.2010-2443","volume":"96","author":"L Sandret","year":"2011","unstructured":"Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96:1327\u20131335. https:\/\/doi.org\/10.1210\/jc.2010-2443","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR63","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR64","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12020-014-0206-1","volume":"46","author":"M Marazuela","year":"2014","unstructured":"Marazuela M, Ramos-Levi A, Sampedro-Nunez M, Bernabeu I (2014) Cabergoline treatment in acromegaly: pros. Endocrine 46:215\u2013219. https:\/\/doi.org\/10.1007\/s12020-014-0206-1","journal-title":"Endocrine"},{"key":"4670_CR65","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s12020-014-0183-4","volume":"46","author":"L Kasuki","year":"2014","unstructured":"Kasuki L, Vieira Neto L, Gadelha MR (2014) Cabergoline treatment in acromegaly: cons. Endocrine 46:220\u2013225. https:\/\/doi.org\/10.1007\/s12020-014-0183-4","journal-title":"Endocrine"},{"key":"4670_CR66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12020-018-1729-7","volume":"63","author":"LP Leonart","year":"2019","unstructured":"Leonart LP, Tonin FS, Ferreira VL, Fernandez-Llimos F, Pontarolo R (2019) Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine 63:18\u201326. https:\/\/doi.org\/10.1007\/s12020-018-1729-7","journal-title":"Endocrine"},{"key":"4670_CR67","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1530\/EJE-21-0239","volume":"185","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Fuhrer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J, Hey-Hadavi J, Camacho-Hubner C, Wajnrajch MP, Valluri SR, Palladino AA, Gomez R, Salvatori R (2021) More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol 185:525\u2013538. https:\/\/doi.org\/10.1530\/EJE-21-0239","journal-title":"Eur J Endocrinol"},{"key":"4670_CR68","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4158\/EP14330.OR","volume":"21","author":"PU Freda","year":"2015","unstructured":"Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ (2015) Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract 21:264\u2013274. https:\/\/doi.org\/10.4158\/EP14330.OR","journal-title":"Endocr Pract"},{"key":"4670_CR69","doi-asserted-by":"publisher","first-page":"bvad104","DOI":"10.1210\/jendso\/bvad104","volume":"7","author":"M Fleseriu","year":"2023","unstructured":"Fleseriu M, Barkan A, Brue T, Duquesne E, Houchard A, Del Pilar SM, Ribeiro-Oliveira A Jr, Melmed S (2023) Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis. J Endocr Soc 7:bvad104. https:\/\/doi.org\/10.1210\/jendso\/bvad104","journal-title":"J Endocr Soc"},{"key":"4670_CR70","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-20-0767","volume":"184","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP, Angelini F, Liverana L, Gessi M, Carmelo A, Rindi G, Giustina A, Fleseriu M, Pontecorvi A, De Marinis L, Bianchi A (2021) Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol 184:217\u2013229. https:\/\/doi.org\/10.1530\/EJE-20-0767","journal-title":"Eur J Endocrinol"},{"key":"4670_CR71","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s12020-021-02711-3","volume":"73","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Visconti F, Rossi L, Donfrancesco F, Fleseriu CM, Mirra F, Pontecorvi A, Giustina A, Fleseriu M, De Marinis L, Bianchi A (2021) Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. Endocrine 73:658\u2013666. https:\/\/doi.org\/10.1007\/s12020-021-02711-3","journal-title":"Endocrine"},{"key":"4670_CR72","doi-asserted-by":"publisher","unstructured":"Bonert V, Mirocha J, Carmichael J, Yuen KCJ, Araki T, Melmed S (2020) Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial. J Clin Endocrinol Metab 105. https:\/\/doi.org\/10.1210\/clinem\/dgaa444","DOI":"10.1210\/clinem\/dgaa444"},{"key":"4670_CR73","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/jc.2017-02017","volume":"103","author":"A Muhammad","year":"2018","unstructured":"Muhammad A, van der Lely AJ, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen J, Neggers S (2018) Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). J Clin Endocrinol Metab 103:586\u2013595. https:\/\/doi.org\/10.1210\/jc.2017-02017","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR74","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/EJE-18-0353","volume":"179","author":"A Muhammad","year":"2018","unstructured":"Muhammad A, Coopmans EC, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen J, van der Lely AJ, Neggers S (2018) Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study. Eur J Endocrinol 179:269\u2013277. https:\/\/doi.org\/10.1530\/EJE-18-0353","journal-title":"Eur J Endocrinol"},{"key":"4670_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/17446651.2016.1222899","volume":"12","author":"LFS Grasso","year":"2017","unstructured":"Grasso LFS, Auriemma RS, Pivonello R, Colao A (2017) Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly. Expert Rev Endocrinol Metab 12:73\u201385. https:\/\/doi.org\/10.1080\/17446651.2016.1222899","journal-title":"Expert Rev Endocrinol Metab"},{"key":"4670_CR76","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11102-012-0382-z","volume":"16","author":"I Bernabeu","year":"2013","unstructured":"Bernabeu I, Alvarez-Escola C, Paniagua AE, Lucas T, Pavon I, Cabezas-Agricola JM, Casanueva FF, Marazuela M (2013) Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 16:101\u2013108. https:\/\/doi.org\/10.1007\/s11102-012-0382-z","journal-title":"Pituitary"},{"key":"4670_CR77","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jama.2023.11305","volume":"330","author":"M Reincke","year":"2023","unstructured":"Reincke M, Fleseriu M (2023) Cushing Syndrome: A Review. JAMA 330:170\u2013181. https:\/\/doi.org\/10.1001\/jama.2023.11305","journal-title":"JAMA"},{"key":"4670_CR78","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9:847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4670_CR79","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41574-023-00868-7","volume":"19","author":"M Fleseriu","year":"2023","unstructured":"Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, Langlois F, Melmed S (2023) An individualized approach to the management of Cushing disease. Nat Rev Endocrinol 19:581\u2013599. https:\/\/doi.org\/10.1038\/s41574-023-00868-7","journal-title":"Nat Rev Endocrinol"},{"key":"4670_CR80","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed S (2020) Pituitary-Tumor Endocrinopathies. N Engl J Med 382:937\u2013950. https:\/\/doi.org\/10.1056\/NEJMra1810772","journal-title":"N Engl J Med"},{"key":"4670_CR81","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A, Endocrine S (2015) Treatment of Cushing\u2019s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100:2807\u20132831. https:\/\/doi.org\/10.1210\/jc.2015-1818","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR82","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, Pasireotide BSG (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366:914\u2013924. https:\/\/doi.org\/10.1056\/NEJMoa1105743","journal-title":"N Engl J Med"},{"key":"4670_CR83","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","volume":"6","author":"A Lacroix","year":"2018","unstructured":"Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK, Newell-Price J, Pasireotide GSG (2018) Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 6:17\u201326. https:\/\/doi.org\/10.1016\/S2213-8587(17)30326-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4670_CR84","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/cen.14081","volume":"91","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M, Petersenn S, Biller BMK, Kadioglu P, De Block C, T\u2019Sjoen G, Vantyghem MC, Tauchmanova L, Wojna J, Roughton M, Lacroix A, Newell-Price J (2019) Long-term efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: A Phase III extension study. Clin Endocrinol (Oxf) 91:776\u2013785. https:\/\/doi.org\/10.1111\/cen.14081","journal-title":"Clin Endocrinol (Oxf)"},{"key":"4670_CR85","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11102-019-00984-6","volume":"22","author":"L Manetti","year":"2019","unstructured":"Manetti L, Deutschbein T, Schopohl J, Yuen KCJ, Roughton M, Kriemler-Krahn U, Tauchmanova L, Maamari R, Giordano C (2019) Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing\u2019s disease: interim results from a long-term real-world evidence study. Pituitary 22:542\u2013551. https:\/\/doi.org\/10.1007\/s11102-019-00984-6","journal-title":"Pituitary"},{"key":"4670_CR86","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40618-020-01246-0","volume":"43","author":"A Lacroix","year":"2020","unstructured":"Lacroix A, Bronstein MD, Schopohl J, Delibasi T, Salvatori R, Li Y, Barkan A, Suzaki N, Tauchmanova L, Ortmann CE, Ravichandran S, Petersenn S, Pivonello R (2020) Long-acting pasireotide improves clinical signs and quality of life in Cushing\u2019s disease: results from a phase III study. J Endocrinol Invest 43:1613\u20131622. https:\/\/doi.org\/10.1007\/s40618-020-01246-0","journal-title":"J Endocrinol Invest"},{"key":"4670_CR87","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/EJE-19-0695","volume":"182","author":"J Newell-Price","year":"2020","unstructured":"Newell-Price J, Pivonello R, Tabarin A, Fleseriu M, Witek P, Gadelha MR, Petersenn S, Tauchmanova L, Ravichandran S, Gupta P, Lacroix A, Biller BMK (2020) Use of late-night salivary cortisol to monitor response to medical treatment in Cushing\u2019s disease. Eur J Endocrinol 182:207\u2013217. https:\/\/doi.org\/10.1530\/EJE-19-0695","journal-title":"Eur J Endocrinol"},{"key":"4670_CR88","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM, Pasireotide BSG (2014) Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a Phase III study. Clin Endocrinol (Oxf) 81:408\u2013417. https:\/\/doi.org\/10.1111\/cen.12431","journal-title":"Clin Endocrinol (Oxf)"},{"key":"4670_CR89","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40618-020-01335-0","volume":"43","author":"F Gatto","year":"2020","unstructured":"Gatto F, Arvigo M, Ferone D (2020) Somatostatin receptor expression and patients\u2019 response to targeted medical treatment in pituitary tumors: evidences and controversies. J Endocrinol Invest 43:1543\u20131553. https:\/\/doi.org\/10.1007\/s40618-020-01335-0","journal-title":"J Endocrinol Invest"},{"key":"4670_CR90","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","volume":"24","author":"SL Samson","year":"2021","unstructured":"Samson SL, Gu F, Feldt-Rasmussen U, Zhang S, Yu Y, Witek P, Kalra P, Pedroncelli AM, Pultar P, Jabbour N, Paul M, Bolanowski M (2021) Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. Pituitary 24:887\u2013903. https:\/\/doi.org\/10.1007\/s11102-021-01161-4","journal-title":"Pituitary"},{"key":"4670_CR91","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1530\/EJE-16-0662","volume":"176","author":"A Ferriere","year":"2017","unstructured":"Ferriere A, Cortet C, Chanson P, Delemer B, Caron P, Chabre O, Reznik Y, Bertherat J, Rohmer V, Briet C, Raingeard I, Castinetti F, Beckers A, Vroonen L, Maiter D, Cephise-Velayoudom FL, Nunes ML, Haissaguerre M, Tabarin A (2017) Cabergoline for Cushing\u2019s disease: a large retrospective multicenter study. Eur J Endocrinol 176:305\u2013314. https:\/\/doi.org\/10.1530\/EJE-16-0662","journal-title":"Eur J Endocrinol"},{"key":"4670_CR92","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s40618-021-01661-x","volume":"45","author":"R Pivonello","year":"2022","unstructured":"Pivonello R, Pivonello C, Simeoli C, De Martino MC, Colao A (2022) The dopaminergic control of Cushing\u2019s syndrome. J Endocrinol Invest 45:1297\u20131315. https:\/\/doi.org\/10.1007\/s40618-021-01661-x","journal-title":"J Endocrinol Invest"},{"key":"4670_CR93","doi-asserted-by":"publisher","first-page":"732240","DOI":"10.3389\/fendo.2021.732240","volume":"12","author":"J Simoes Correa Galendi","year":"2021","unstructured":"Simoes Correa Galendi J, Correa Neto ANS, Demetres M, Boguszewski CL, Nogueira V (2021) Effectiveness of Medical Treatment of Cushing\u2019s Disease: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 12:732240. https:\/\/doi.org\/10.3389\/fendo.2021.732240","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4670_CR94","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1530\/EJE-20-0380","volume":"183","author":"SM Constantinescu","year":"2020","unstructured":"Constantinescu SM, Driessens N, Lefebvre A, Furnica RM, Corvilain B, Maiter D (2020) Etomidate infusion at low doses is an effective and safe treatment for severe Cushing\u2019s syndrome outside intensive care. Eur J Endocrinol 183:161\u2013167. https:\/\/doi.org\/10.1530\/EJE-20-0380","journal-title":"Eur J Endocrinol"},{"key":"4670_CR95","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, Caron P, Luca F, Donadille B, Vantyghem MC, Bihan H, Delemer B, Raverot G, Motte E, Philippon M, Morange I, Conte-Devolx B, Quinquis L, Martinie M, Vezzosi D, Le Bras M, Baudry C, Christin-Maitre S, Goichot B, Chanson P, Young J, Chabre O, Tabarin A, Bertherat J, Brue T (2014) Ketoconazole in Cushing\u2019s disease: is it worth a try? J Clin Endocrinol Metab 99:1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2013-3628","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR96","doi-asserted-by":"publisher","first-page":"1017331","DOI":"10.3389\/fendo.2022.1017331","volume":"13","author":"C Viecceli","year":"2022","unstructured":"Viecceli C, Mattos ACV, Costa MCB, de Melo RB, Rodrigues TDC, Czepielewski MA (2022) Evaluation of ketoconazole as a treatment for Cushing\u2019s disease in a retrospective cohort. Front Endocrinol (Lausanne) 13:1017331. https:\/\/doi.org\/10.3389\/fendo.2022.1017331","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4670_CR97","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1530\/EJE-17-0886","volume":"178","author":"J Young","year":"2018","unstructured":"Young J, Bertherat J, Vantyghem MC, Chabre O, Senoussi S, Chadarevian R, Castinetti F, Compassionalteuse P (2018) Hepatic safety of ketoconazole in Cushing\u2019s syndrome: results of a Compassionate Use Programme in France. Eur J Endocrinol 178:447\u2013458. https:\/\/doi.org\/10.1530\/EJE-17-0886","journal-title":"Eur J Endocrinol"},{"key":"4670_CR98","doi-asserted-by":"publisher","first-page":"e1618","DOI":"10.1210\/clinem\/dgaa989","volume":"106","author":"SG Creemers","year":"2021","unstructured":"Creemers SG, Feelders RA, de Jong FH, Franssen GJH, de Rijke YB, van Koetsveld PM, Hofland LJ (2021) Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing\u2019s Syndrome Treatment. J Clin Endocrinol Metab 106:e1618\u2013e1630. https:\/\/doi.org\/10.1210\/clinem\/dgaa989","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR99","doi-asserted-by":"publisher","first-page":"101490","DOI":"10.1016\/j.beem.2021.101490","volume":"35","author":"EV Varlamov","year":"2021","unstructured":"Varlamov EV, Han AJ, Fleseriu M (2021) Updates in adrenal steroidogenesis inhibitors for Cushing\u2019s syndrome - A practical guide. Best Pract Res Clin Endocrinol Metab 35:101490. https:\/\/doi.org\/10.1016\/j.beem.2021.101490","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"4670_CR100","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","volume":"7","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M, Pivonello R, Elenkova A, Salvatori R, Auchus RJ, Feelders RA, Geer EB, Greenman Y, Witek P, Cohen F, Biller BMK (2019) Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol 7:855\u2013865. https:\/\/doi.org\/10.1016\/S2213-8587(19)30313-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4670_CR101","doi-asserted-by":"publisher","first-page":"595894","DOI":"10.3389\/fendo.2021.595894","volume":"12","author":"R Pivonello","year":"2021","unstructured":"Pivonello R, Elenkova A, Fleseriu M, Feelders RA, Witek P, Greenman Y, Geer EB, Perotti P, Saiegh L, Cohen F, Arnaldi G (2021) Levoketoconazole in the Treatment of Patients With Cushing\u2019s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. Front Endocrinol (Lausanne) 12:595894. https:\/\/doi.org\/10.3389\/fendo.2021.595894","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4670_CR102","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s11102-022-01263-7","volume":"25","author":"R Pivonello","year":"2022","unstructured":"Pivonello R, Zacharieva S, Elenkova A, Toth M, Shimon I, Stigliano A, Badiu C, Brue T, Georgescu CE, Tsagarakis S, Cohen F, Fleseriu M (2022) Levoketoconazole in the treatment of patients with endogenous Cushing\u2019s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pituitary 25:911\u2013926. https:\/\/doi.org\/10.1007\/s11102-022-01263-7","journal-title":"Pituitary"},{"key":"4670_CR103","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1530\/EJE-22-0506","volume":"187","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Auchus RJ, Greenman Y, Zacharieva S, Geer EB, Salvatori R, Pivonello R, Feldt-Rasmussen U, Kennedy L, Buchfelder M, Biller BM, Cohen F, Heaney AP (2022) Levoketoconazole treatment in endogenous Cushing\u2019s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes. Eur J Endocrinol 187:859\u2013871. https:\/\/doi.org\/10.1530\/EJE-22-0506","journal-title":"Eur J Endocrinol"},{"key":"4670_CR104","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-010.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O\u2019Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK, Investigators L (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8:748\u2013761. https:\/\/doi.org\/10.1016\/S2213-8587(20)30240-010.1016\/S2213-8587(20)30240-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4670_CR105","doi-asserted-by":"publisher","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","volume":"107","author":"M Gadelha","year":"2022","unstructured":"Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A, Witek P, Belaya Z, Yu Y, Liao Z, Ku CHC, Carvalho D, Roughton M, Wojna J, Pedroncelli AM, Snyder PJ (2022) Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. J Clin Endocrinol Metab 107:e2882\u2013e2895. https:\/\/doi.org\/10.1210\/clinem\/dgac178","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR106","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11102-022-01280-6","volume":"25","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Biller BMK, Bertherat J, Young J, Hatipoglu B, Arnaldi G, O\u2019Connell P, Izquierdo M, Pedroncelli AM, Pivonello R (2022) Long-term efficacy and safety of osilodrostat in Cushing\u2019s disease: final results from a Phase II study with an optional extension phase (LINC 2). Pituitary 25:959\u2013970. https:\/\/doi.org\/10.1007\/s11102-022-01280-6","journal-title":"Pituitary"},{"key":"4670_CR107","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-22-0317","volume":"187","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Newell-Price J, Pivonello R, Shimatsu A, Auchus RJ, Scaroni C, Belaya Z, Feelders RA, Vila G, Houde G, Walia R, Izquierdo M, Roughton M, Pedroncelli AM, Biller BMK (2022) Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension. Eur J Endocrinol 187:531\u2013541. https:\/\/doi.org\/10.1530\/EJE-22-0317","journal-title":"Eur J Endocrinol"},{"key":"4670_CR108","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11102-022-01218-y","volume":"25","author":"X He","year":"2022","unstructured":"He X, Findling JW, Auchus RJ (2022) Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome. Pituitary 25:393\u2013403. https:\/\/doi.org\/10.1007\/s11102-022-01218-y","journal-title":"Pituitary"},{"key":"4670_CR109","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11102-020-01097-1","volume":"24","author":"C Fontaine-Sylvestre","year":"2021","unstructured":"Fontaine-Sylvestre C, Letourneau-Guillon L, Moumdjian RA, Berthelet F, Lacroix A (2021) Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing\u2019s disease. Pituitary 24:207\u2013215. https:\/\/doi.org\/10.1007\/s11102-020-01097-1","journal-title":"Pituitary"},{"key":"4670_CR110","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1530\/EJE-22-0320","volume":"187","author":"HF Nowotny","year":"2022","unstructured":"Nowotny HF, Braun L, Vogel F, Bidlingmaier M, Reincke M, Tschaidse L, Auer MK, Lottspeich C, Wudy SA, Hartmann MF, Hawley J, Adaway JE, Keevil B, Schilbach K, Reisch N (2022) 11-Oxygenated C19 steroids are the predominant androgens responsible for hyperandrogenemia in Cushing\u2019s disease. Eur J Endocrinol 187:663\u2013673. https:\/\/doi.org\/10.1530\/EJE-22-0320","journal-title":"Eur J Endocrinol"},{"key":"4670_CR111","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol 33:6\u201326. https:\/\/doi.org\/10.1007\/s12022-022-09703-7","journal-title":"Endocr Pathol"},{"key":"4670_CR112","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1210\/jendso\/bvab048.1053","volume":"5","author":"LBM Nieman","year":"2021","unstructured":"Nieman LBM, Scaroni CM, Deutschbein T, Mezosi E, Driessens N, Georgescu CE, Hubalewska DA, Berker D, Jarzab BM, Maiter DM, Reincke M, Loli P, Zampetti B, Atmaca A, Badiu C, Beckers AM, Bolanowski M, Cavagnini F, Unger N, Giordano RF, Hanzu FA, Terzolo M, Bostnavaron M, Toth M (2021) Metyrapone treatment in endogenous Cushing\u2019s syndrome: results at week 12 from PROMPT, a prospective international multicenter, open-label, phase III\/IV study. J Endocr Soc 5:515","journal-title":"J Endocr Soc"},{"key":"4670_CR113","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1530\/EJE-22-0208","volume":"187","author":"F Bonnet-Serrano","year":"2022","unstructured":"Bonnet-Serrano F, Poirier J, Vaczlavik A, Laguillier-Morizot C, Blanchet B, Baron S, Guignat L, Bessiene L, Bricaire L, Groussin L, Assie G, Guibourdenche J, Bertherat J (2022) Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients. Eur J Endocrinol 187:315\u2013322. https:\/\/doi.org\/10.1530\/EJE-22-0208","journal-title":"Eur J Endocrinol"},{"key":"4670_CR114","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C, Investigators SS (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 97:2039\u20132049. https:\/\/doi.org\/10.1210\/jc.2011-3350","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR115","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1210\/jc.2014-1843","volume":"99","author":"M Fleseriu","year":"2014","unstructured":"Fleseriu M, Findling JW, Koch CA, Schlaffer SM, Buchfelder M, Gross C (2014) Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab 99:3718\u20133727. https:\/\/doi.org\/10.1210\/jc.2014-1843","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR116","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","volume":"21","author":"LHA Broersen","year":"2018","unstructured":"Broersen LHA, Jha M, Biermasz NR, Pereira AM, Dekkers OM (2018) Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis. Pituitary 21:631\u2013641. https:\/\/doi.org\/10.1007\/s11102-018-0897-z","journal-title":"Pituitary"},{"key":"4670_CR117","doi-asserted-by":"publisher","first-page":"1165681","DOI":"10.3389\/fendo.2023.1165681","volume":"14","author":"RA Feelders","year":"2023","unstructured":"Feelders RA, Fleseriu M, Kadioglu P, Bex M, Gonzalez-Devia D, Boguszewski CL, Yavuz DG, Patino H, Pedroncelli AM, Maamari R, Chattopadhyay A, Biller BMK, Pivonello R (2023) Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing\u2019s disease. Front Endocrinol (Lausanne) 14:1165681. https:\/\/doi.org\/10.3389\/fendo.2023.1165681","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4670_CR118","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s11102-022-01238-8","volume":"25","author":"MR Gadelha","year":"2022","unstructured":"Gadelha MR, Wildemberg LE, Shimon I (2022) Pituitary acting drugs: cabergoline and pasireotide. Pituitary 25:722\u2013725. https:\/\/doi.org\/10.1007\/s11102-022-01238-8","journal-title":"Pituitary"},{"key":"4670_CR119","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/jcph.400","volume":"54","author":"HK Greenblatt","year":"2014","unstructured":"Greenblatt HK, Greenblatt DJ (2014) Liver injury associated with ketoconazole: review of the published evidence. J Clin Pharmacol 54:1321\u20131329. https:\/\/doi.org\/10.1002\/jcph.400","journal-title":"J Clin Pharmacol"},{"key":"4670_CR120","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1210\/jc.2012-3582","volume":"98","author":"OM Dekkers","year":"2013","unstructured":"Dekkers OM, Horvath-Puho E, Jorgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, Pereira AM, Sorensen HT (2013) Multisystem morbidity and mortality in Cushing\u2019s syndrome: a cohort study. J Clin Endocrinol Metab 98:2277\u20132284. https:\/\/doi.org\/10.1210\/jc.2012-3582","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR121","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1530\/EJE-21-0162","volume":"185","author":"C De Herdt","year":"2021","unstructured":"De Herdt C, Philipse E, De Block C (2021) ENDOCRINE TUMOURS: Thyrotropin-secreting pituitary adenoma: a structured review of 535 adult cases. Eur J Endocrinol 185:R65\u2013R74. https:\/\/doi.org\/10.1530\/EJE-21-0162","journal-title":"Eur J Endocrinol"},{"key":"4670_CR122","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3171\/2014.7.JNS1471","volume":"121","author":"S Yamada","year":"2014","unstructured":"Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J, Inoshita N (2014) Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. J Neurosurg 121:1462\u20131473. https:\/\/doi.org\/10.3171\/2014.7.JNS1471","journal-title":"J Neurosurg"},{"key":"4670_CR123","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1507\/endocrj.EJ14-0118","volume":"62","author":"N Fukuhara","year":"2015","unstructured":"Fukuhara N, Horiguchi K, Nishioka H, Suzuki H, Takeshita A, Takeuchi Y, Inoshita N, Yamada S (2015) Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma. Endocr J 62:21\u201327. https:\/\/doi.org\/10.1507\/endocrj.EJ14-0118","journal-title":"Endocr J"},{"key":"4670_CR124","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000351007","volume":"2","author":"P Beck-Peccoz","year":"2013","unstructured":"Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL (2013) 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 2:76\u201382. https:\/\/doi.org\/10.1159\/000351007","journal-title":"Eur Thyroid J"},{"key":"4670_CR125","doi-asserted-by":"publisher","unstructured":"Ntali G, Capatina C (2022) Updating the Landscape for Functioning Gonadotroph Tumors. Medicina (Kaunas) 58. https:\/\/doi.org\/10.3390\/medicina58081071","DOI":"10.3390\/medicina58081071"},{"key":"4670_CR126","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1021\/acsmedchemlett.2c00431","volume":"14","author":"J Zhao","year":"2023","unstructured":"Zhao J, Wang S, Markison S, Kim SH, Han S, Chen M, Kusnetzow AK, Rico-Bautista E, Johns M, Luo R, Struthers RS, Madan A, Zhu Y, Betz SF (2023) Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist. ACS Med Chem Lett 14:66\u201374. https:\/\/doi.org\/10.1021\/acsmedchemlett.2c00431","journal-title":"ACS Med Chem Lett"},{"key":"4670_CR127","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00280-018-3734-1","volume":"83","author":"M Pavel","year":"2019","unstructured":"Pavel M, Borson-Chazot F, Cailleux A, Horsch D, Lahner H, Pivonello R, Tauchmanova L, Darstein C, Olsson H, Tiberg F, Ferone D (2019) Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. Cancer Chemother Pharmacol 83:375\u2013385. https:\/\/doi.org\/10.1007\/s00280-018-3734-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4670_CR128","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1210\/clinem\/dgac588","volume":"108","author":"NA Liu","year":"2023","unstructured":"Liu NA, Ben-Shlomo A, Carmichael JD, Wang C, Swerdloff RS, Heaney AP, Barkhoudarian G, Kelly D, Noureddin M, Lu L, Desai M, Stolyarov Y, Yuen K, Mamelak AN, Mirocha J, Tighiouart M, Melmed S (2023) Treatment of Cushing Disease With Pituitary-Targeting Seliciclib. J Clin Endocrinol Metab 108:726\u2013735. https:\/\/doi.org\/10.1210\/clinem\/dgac588","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR129","doi-asserted-by":"publisher","first-page":"662865","DOI":"10.3389\/fendo.2021.662865","volume":"12","author":"R Pivonello","year":"2021","unstructured":"Pivonello R, Bancos I, Feelders RA, Kargi AY, Kerr JM, Gordon MB, Mariash CN, Terzolo M, Ellison N, Moraitis AG (2021) Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. Front Endocrinol (Lausanne) 12:662865. https:\/\/doi.org\/10.3389\/fendo.2021.662865","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4670_CR130","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","volume":"108","author":"P Burman","year":"2023","unstructured":"Burman P, Casar-Borota O, Perez-Rivas LG, Dekkers OM (2023) Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. J Clin Endocrinol Metab 108:1585\u20131601. https:\/\/doi.org\/10.1210\/clinem\/dgad098","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR131","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","volume":"187","author":"P Burman","year":"2022","unstructured":"Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, Theodoropoulou M, Raverot G, Dekkers OM, dagger ESEsc, (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187:593\u2013605. https:\/\/doi.org\/10.1530\/EJE-22-0440","journal-title":"Eur J Endocrinol"},{"key":"4670_CR132","doi-asserted-by":"publisher","first-page":"774686","DOI":"10.3389\/fendo.2021.774686","volume":"12","author":"L Das","year":"2021","unstructured":"Das L, Gupta N, Dutta P, Walia R, Vaiphei K, Rai A, Radotra BD, Gupta K, Sreedharanunni S, Ahuja CK, Bhansali A, Tripathi M, Sood R, Dhandapani S (2021) Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas. Front Endocrinol (Lausanne) 12:774686. https:\/\/doi.org\/10.3389\/fendo.2021.774686","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4670_CR133","doi-asserted-by":"publisher","first-page":"101713","DOI":"10.1016\/j.beem.2022.101713","volume":"36","author":"A McCormack","year":"2022","unstructured":"McCormack A (2022) Temozolomide in aggressive pituitary tumours and pituitary carcinomas. Best Pract Res Clin Endocrinol Metab 36:101713. https:\/\/doi.org\/10.1016\/j.beem.2022.101713","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"4670_CR134","doi-asserted-by":"publisher","first-page":"bvab190","DOI":"10.1210\/jendso\/bvab190","volume":"6","author":"L Das","year":"2022","unstructured":"Das L, Rai A, Salunke P, Ahuja CK, Sood A, Radotra BD, Sood R, Korbonits M, Dutta P (2022) Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes. J Endocr Soc 6:bvab190. https:\/\/doi.org\/10.1210\/jendso\/bvab190","journal-title":"J Endocr Soc"},{"key":"4670_CR135","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM, European Society of E","year":"2018","unstructured":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM, European Society of E (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1\u2013G24. https:\/\/doi.org\/10.1530\/EJE-17-0796","journal-title":"Eur J Endocrinol"},{"key":"4670_CR136","doi-asserted-by":"publisher","first-page":"101712","DOI":"10.1016\/j.beem.2022.101712","volume":"36","author":"G Raverot","year":"2022","unstructured":"Raverot G, Ilie MD (2022) Immunotherapy in pituitary carcinomas and aggressive pituitary tumors. Best Pract Res Clin Endocrinol Metab 36:101712. https:\/\/doi.org\/10.1016\/j.beem.2022.101712","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"4670_CR137","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","volume":"106","author":"O Cooper","year":"2021","unstructured":"Cooper O, Bonert VS, Rudnick J, Pressman BD, Lo J, Salvatori R, Yuen KCJ, Fleseriu M, Melmed S (2021) EGFR\/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. J Clin Endocrinol Metab 106:e917\u2013e925. https:\/\/doi.org\/10.1210\/clinem\/dgaa805","journal-title":"J Clin Endocrinol Metab"},{"key":"4670_CR138","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11154-020-09554-9","volume":"21","author":"S Petersenn","year":"2020","unstructured":"Petersenn S, Heaney AP (2020) Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas. Rev Endocr Metab Disord 21:277\u2013286. https:\/\/doi.org\/10.1007\/s11154-020-09554-9","journal-title":"Rev Endocr Metab Disord"},{"key":"4670_CR139","doi-asserted-by":"publisher","first-page":"K21","DOI":"10.1530\/EJE-19-0279","volume":"181","author":"EC Coopmans","year":"2019","unstructured":"Coopmans EC, van Meyel SWF, Pieterman KJ, van Ipenburg JA, Hofland LJ, Donga E, Daly AF, Beckers A, van der Lely AJ, Neggers S (2019) Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma. Eur J Endocrinol 181:K21\u2013K27. https:\/\/doi.org\/10.1530\/EJE-19-0279","journal-title":"Eur J Endocrinol"},{"key":"4670_CR140","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tem.2009.12.003","volume":"21","author":"A Ben-Shlomo","year":"2010","unstructured":"Ben-Shlomo A, Melmed S (2010) Pituitary somatostatin receptor signaling. Trends Endocrinol Metab 21:123\u2013133. https:\/\/doi.org\/10.1016\/j.tem.2009.12.003","journal-title":"Trends Endocrinol Metab"},{"key":"4670_CR141","doi-asserted-by":"publisher","first-page":"T69","DOI":"10.1530\/JME-17-0311","volume":"61","author":"F Hakuno","year":"2018","unstructured":"Hakuno F, Takahashi SI (2018) IGF1 receptor signaling pathways. J Mol Endocrinol 61:T69\u2013T86. https:\/\/doi.org\/10.1530\/JME-17-0311","journal-title":"J Mol Endocrinol"},{"key":"4670_CR142","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","volume":"34","author":"M Theodoropoulou","year":"2013","unstructured":"Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34:228\u2013252. https:\/\/doi.org\/10.1016\/j.yfrne.2013.07.005","journal-title":"Front Neuroendocrinol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04670-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04670-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04670-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T13:10:45Z","timestamp":1717420245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04670-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":142,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["4670"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04670-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.F. has received grants to the institution from Crinetics, Ionis, Recordati, Sparrow, and Xeris and occasional consulting fees from Amryt, Camurus, Crinetics, Ipsen, Recordati, Sparrow, and Xeris.C.C. has received occasional speaker and consulting fees from Pfizer and Ipsen.FAH has received grants to the institution from HRPharma and Camurus and occasional consulting fees from Recordati, Pfizer, Ipsen and HRPharma.JMHA has received occasional speaker and consulting fees from Ipsen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}